ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2960

Cardiovascular and Cerebrovascular Comorbidities of Juvenile Dermatomyositis in United States Children

Jonathan I. Silverberg1, Lauren Kwa2, Michael C. Kwa2, Anne Laumann2 and Kaveh Ardalan3,4, 1Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cardiovascular disease, juvenile dermatomyositis, pediatric rheumatology and pediatrics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 8, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Lupus, Dermatomyositis, and Scleroderma

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose:

Juvenile dermatomyositis (JDM) is an autoimmune disease that causes vasculopathy and inflammation of skin and muscles. Previous studies in adult dermatomyositis suggest increased risks of cardiovascular disease, but such assessments in JDM remain underexplored.  This study evaluates cardiovascular risk factors and outcomes in children with versus without JDM.

Methods:

Data were analyzed from the 2002-2012 Nationwide Inpatient Sample, containing a representative 20% stratified sample of all hospitalizations in the United States. Primary (i.e. condition chiefly responsible for inpatient admission) vs secondary diagnoses of JDM (age <18 years) were identified using the previously validated ICD-9-CM code 710.3. Comorbidities were identified using ICD-9-CM codes in NIS for each patient discharge. Survey weighted logistic regression models were used to determine associations of JDM with comorbidities. Multivariate models included age, sex and race/ethnicity (model-1), as well as obesity, hypertension and diabetes (model-2) as binary covariates. A 2-sided p-value <0.05 was considered statistically significant.

Results:

From 2002-2012, 909 primary and 498 secondary diagnoses of JDM were identified (from 14,535,620 pediatric hospital discharges). JDM inpatients were 34.6% male, 49.0% white, 18.5% black and 24.1% Hispanic. Twelve of 13 cardiovascular comorbidities were significantly associated with JDM (Table 1). Hypertension was the most common comorbidity in children with JDM (8.78% JDM patients vs 0.43% those without JDM, OR [95% CI]: 22.25 [15.51-31.92]). JDM was also associated with higher rates of obesity, uncomplicated diabetes, and lipid abnormalities. JDM inpatients had higher odds of cardio/cerebrovascular disorders, i.e. peripheral/visceral atherosclerosis, late effects of cerebrovascular disease, personal history transient ischemic attack/cerebral infarction, pulmonary circulatory disorder, arrhythmia, bradycardia, and hypotension. In multivariate regression models adjusting for age, gender and race/ethnicity, associations with JDM remained significant in 10 of 13 comorbidities.

Conclusion:

JDM is associated with higher odds of cardiovascular and cerebrovascular risk factors and disease. The possible interaction of chronic inflammation, vasculopathy, and treatment side effects with sociodemographic and cardiovascular risk factors requires further study.



Disclosure: J. I. Silverberg, None; L. Kwa, None; M. C. Kwa, None; A. Laumann, None; K. Ardalan, None.

To cite this abstract in AMA style:

Silverberg JI, Kwa L, Kwa MC, Laumann A, Ardalan K. Cardiovascular and Cerebrovascular Comorbidities of Juvenile Dermatomyositis in United States Children [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/cardiovascular-and-cerebrovascular-comorbidities-of-juvenile-dermatomyositis-in-united-states-children/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-and-cerebrovascular-comorbidities-of-juvenile-dermatomyositis-in-united-states-children/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology